Diabetic Neuropathy Market
Diabetic Neuropathy Market Study by Peripheral Neuropathy, Autonomic Neuropathy, and Proximal Neuropathy from 2023 to 2033
Analysis of Diabetic Neuropathy Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Diabetic Neuropathy Market Outlook (2023 to 2033)
The global diabetic neuropathy market is valued at US$ 4.2 billion in 2023 and is estimated to reach US$ 8 billion by the end of 2033. Global demand for diabetic neuropathy is forecasted to increase steadily at 6.6% CAGR over the next ten years.
Diabetes has the potential to damage an individual’s nerves and this damage caused is termed diabetic neuropathy and mostly affects the feet and legs. Diabetic neuropathy symptoms can be mild for some while severe for others causing numbness, issues with controlling the heart rate, etc., and can even prove fatal in certain cases if not treated with proper attention and care.
The world has witnessed a notable increase in the incidence of chronic diseases around the world and this trend is projected to significantly boost demand for diabetic neuropathy treatment in the future since cases of diabetes are rising rapidly around the world. Growing focus on health, rising investments in medical research, increasing healthcare expenditure, growing awareness regarding diabetic neuropathy, poor lifestyle habits, high incidence of obesity, and an expanding aging population are key aspects that could promulgate the demand for diabetic nerve treatment products and therapies across the forecast period.
Rising availability of over-the-counter diabetic neuropathy treatment medications is anticipated to create lucrative growth opportunities for established as well as upcoming diabetic neuropathy drug manufacturers in the future. Homeopathic diabetic neuropathy, multivitamins for diabetic neuropathy, and diabetic neuropathy holistic treatment are some of the popular treatments available in the marketplace at present.
Increasing advancements in research and development are predicted to bolster the demand for advanced treatment therapies and products such as infrared therapy for diabetic neuropathy going forward.
On the flip side, the high availability of alternative therapies for diabetic neuropathy treatment and the high costs of diabetic neuropathy therapeutics and drugs are extrapolated to thwart overall market development through 2033.
| Report Attributes | Details |
|---|---|
| Market Size (2023) | US$ 4.2 Billion |
| Projected Market Value (2033F) | US$ 8 Billion |
| Global Market Growth Rate (2023 to 2033) | 6.6% CAGR |
| Market Share Peripheral Neuropathy (2022) | >50% |
| Proximal Neuropathy Segment Growth Rate (2023 to 2033) | 5.4% CAGR |
| Peripheral Neuropathy Segment Growth Rate (2023 to 2033) | 5.8% CAGR |
| Key Companies Profiled | NeuroMetrix Inc.; GlaxoSmithKline plc; Johnson & Johnson (Janssen Global Services LLC); Lupin Limited; Astellas Pharma Inc.; Depomed Inc.; Arbor Pharmaceuticals LLC; Boehringer Ingelheim GmbH; Eli Lilly and Company; Glenmark Pharmaceuticals Ltd.; Pfizer Inc. |
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Which Factors are Altering Demand for Neuropathic Pain Treatments?
“Growing Prevalence of Diabetes across the World”
Diabetes has become a renowned worldwide phenomenon that affects millions of people. Adoption of sedentary lifestyles and poor eating habits are at the helm of the rising incidence of diabetes around the world and are expected to bolster demand for novel diabetic neuropathy treatment formulations in the future. The increasing geriatric population across the world is also slated to contribute to the growing prevalence of diabetes and diabetic neuropathy on a global level going forward.
- As per the statistics listed on the International Diabetes Federation (IDF) website, nearly 643 million people are anticipated to be suffering from diabetes by the end of 2030. Nearly 90% of these people are expected to be living with Type 2 diabetes.
“Increasing Investments in R&D on Diabetes Treatment”
Diabetes has become a public health issue, which has led to an increased focus on the research and development of treatments for the condition from the public as well as private sectors. Supportive government initiatives to promote the development of diabetic nerve treatment products are anticipated to uplift market growth over the coming years. Moreover, increasing investments in healthcare R&D by prime biopharmaceutical companies and private sector organizations are also projected to bolster market evolution in the future.
- A new study published by researchers at the Salk Institute in Nature (a leading science journal) on 25th January 2023 revealed that low levels of amino acid serine increased the risk of developing peripheral neuropathy for diabetic mice. These new findings could be used to explore the use of serine supplementation to alleviate the symptoms of neuropathy symptoms and possibly take us one step closer to developing a possible cure.
How are New Companies Transforming Diabetic Neuropathy Care?
“Start-ups Focusing on Development of Novel Treatment Products & Services”
Aspiring diabetic neuropathy treatment companies are focusing on developing novel products that provide diabetic foot pain relief and better help for diabetic neuropathy to revolutionize the marketplace and establish a presence for themselves on a global level.
- Healables, a start-up based in Israel is revolutionizing pain management and chronic pain relief by using a combination of artificial intelligence and embedded electrodes. The electrodes are embedded in an elasticized sleeve that gently vibrates and stimulates cells into self-repair. The device is undergoing trials with diabetic neuropathy patients in the United Kingdom at Derby Teaching Hospitals NHS Foundation Trust.
New entrants in the industry are also focusing on bagging new funds to finance their research and expansion efforts that help them strengthen their stance in the global competitive landscape.
- In August 2022, Yostra Labs, an India-based medtech start-up announced that it had raised US$ 484,164 in a seed funding round that was led by Villgro Innovations Foundation, Indian Angel Network, and other investors. The company has a specialized portfolio of products for the management and diagnosis of peripheral neuropathy. The company was expected to use the raised capital to expand its workforce and marketing teams.
This latest diabetic neuropathy market research report by Fact.MR, a market research and competitive intelligence provider, proffers a comprehensive assessment of how new developments by start-ups are altering product standards, pricing trends, local supply, and safety regulations on a global level.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Country-wise Insights
Will the United States be a Profitable Market for Diabetic Neuropathy Drug Suppliers?
“Growing Obesity to Create Attractive Business Scope”
Obese people are at an increased risk of contracting diabetes and diabetic neuropathy, which makes the United States a highly opportune market because obesity has been increasing at an alarming pace in the country in recent years. Poor lifestyle choices, lack of exercise, consumption of processed foods, and improper nutrition are key factors leading to an increasing prevalence of obesity among the citizens of the United States and driving diabetic neuropathy market growth potential.
Increasing investments in research, the presence of developed healthcare infrastructure, the launch of novel therapeutics for diabetic foot pain relief, and an increasing number of product approvals from regulatory authorities are other prospects that promulgate demand for diabetic nerve pain treatment. Early adoption of diabetic neuropathy treatment drugs and the growing availability of advanced treatments open up new avenues of opportunity for diabetic neuropathy treatment companies in the country.
Why are Investors Focusing on Japan for Diabetic Neuropathy?
“Expanding Geriatric Population Propelling Demand for Diabetic Nerve Pain Treatment”
Japan is a highly remunerative market for established as well as upcoming diabetic neuropathy treatment companies owing to its growing senescent population that is at increased risk of suffering from diabetic foot pain and other health conditions. Increasing investments by the public and private sectors to provide better healthcare for the elderly in Japan are anticipated to bolster market growth in the future.
Diabetic neuropathy natural treatment techniques and the use of natural herbs for diabetic neuropathy are anticipated to be popular in Japan owing to the high popularity and reliance of people on ancient medical practices.
Which Countries in Europe are Lucrative Markets?
“Germany, Portugal, & Ireland to Be Prime Markets in Europe”
Increasing healthcare expenditure and the rising geriatric population are the foremost prospects that are anticipated to uplift diabetic neuropathy treatment demand in the European region over the coming years. The rising number of people affected by diabetes and the increasing availability of novel over-the-counter diabetic neuropathy treatment medications and therapies are also anticipated to bolster market growth in European countries such as Germany, Ireland, Portugal, and the United Kingdom.
Category-wise Insights
Which Disorders Lead the Demand for Diabetic Neuropathy Treatment?
“Proximal & Peripheral Diabetic Neuropathy Generating Majority of Market Revenue”
Based on disorder, the diabetic neuropathy market is segmented into peripheral neuropathy, autonomic neuropathy, proximal neuropathy, and focal neuropathy.
Treatment of peripheral neuropathy is currently limited to pain management and increasing investments in research are projected to bolster the demand for proper treatment through the regeneration of nerves over the coming years. Peripheral neuropathy accounted for more than half of the global market share in 2022 and is poised to register an approximate CAGR of 5.8% over the next ten years.
Meanwhile, growing cases of people suffering from type 2 diabetes are projected to bolster demand for proximal diabetic neuropathy formulations since it is most common in people with type 2 diabetes. Proximal neuropathy is projected to account for nearly 1/4 of the global market share by the end of 2033.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Competitive Landscape :
Leading diabetic neuropathy treatment providers are focusing on hastening their research and development process to launch novel drug formulations and therapies to provide diabetic nerve pain relief.
- In January 2023, Neuralace Medical Inc., a medical technology company announced the enrollment of the first patients for its Axon Therapy and Painful Diabetic Neuropathy (AT-PDN) study with a target of around 80 patients. The study was estimated to be conducted at five clinical sites and led by Dr. Lora Brown at TruWell Health, Florida.
- In November 2020, Helixmith, a biotechnology company based in South Korea announced the start of a new trial for patients with diabetic neuropathy. The company was focusing on using gene therapy to treat diabetic peripheral neuropathy (DPN).
Key Segments of Diabetic Neuropathy Industry Research
-
By Disorder :
- Peripheral Neuropathy
- Autonomic Neuropathy
- Proximal Neuropathy
- Focal Neuropathy
-
By Treatment :
- Drugs
- Analgesic
- Topical
- Capsaicin
- Others
- Opioid
- Morphine
- Others
- NSAIDs
- Ibuprofen
- Naproxen
- Others
- Antidepressants
- TCAs
- Amitriptyline
- Imipramine
- Others
- SNRIs
- Duloxetine
- Others
- SSRIs
- Citalopram
- Paroxetine
- Others
- TCAs
- Anticonvulsant Drugs
- Gabapentin
- Pregabalin
- Topiramate
- Others
- Topical
- Analgesic
- Other Drugs
- Radiotherapy
- Transcutaneous Electrical Nerve Stimulation (TENS)
- Others
- Physiotherapy
- Drugs
-
By Distribution Channel :
- Hospitals
- Clinics
- Retail Pharmacies
- Online Pharmacies
-
By Region :
- North America
- Latin America
- Europe
- APAC
- MEA
Table of Content
- 1. Market Overview
- 2. Market Risks and Trends Assessment
- 3. Market Background and Foundation Data Points
- 4. Key Success Factors
- 5. Global Market Value Analysis 2018 to 2022 and Forecast 2023 to 2033
- 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disorder
- 6.1. Peripheral Neuropathy
- 6.2. Autonomic Neuropathy
- 6.3. Proximal Neuropathy
- 6.4. Focal Neuropathy
- 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment
- 7.1. Drug
- 7.1.1. Analgesic
- 7.1.1.1. Topical
- 7.1.1.1.1. Capsaicin
- 7.1.1.1.2. Others
- 7.1.1.2. Opioids
- 7.1.1.2.1. Morphine
- 7.1.1.2.2. Others
- 7.1.1.3. NSAIDs
- 7.1.1.3.1. Ibuprofen
- 7.1.1.3.2. Naproxen
- 7.1.1.3.3. Others
- 7.1.1.1. Topical
- 7.1.2. Antidepressant
- 7.1.2.1. TCAs
- 7.1.2.1.1. Amitriptyline
- 7.1.2.1.2. Imipramine
- 7.1.2.1.3. Others
- 7.1.2.2. SNRIs
- 7.1.2.2.1. Duloxetine
- 7.1.2.2.2. Others
- 7.1.2.3. SSRIs
- 7.1.2.3.1. Citalopram
- 7.1.2.3.2. Paroxetin
- 7.1.2.3.3. Others
- 7.1.2.1. TCAs
- 7.1.3. Anticonvulsants
- 7.1.3.1. Gabapentin
- 7.1.3.2. Pregabalin
- 7.1.3.3. Topimarate
- 7.1.3.4. Others
- 7.1.3.5. Other Drugs
- 7.1.1. Analgesic
- 7.2. Radiotherapy
- 7.2.1. TENS
- 7.2.2. Others
- 7.3. Physiotherapy
- 7.1. Drug
- 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
- 8.1. Hospitals
- 8.2. Clinics
- 8.3. Retail Pharmacy
- 8.4. Online Pharmacy
- 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
- 9.1. North America
- 9.2. Latin America
- 9.3. Europe
- 9.4. Asia Pacific
- 9.5. Middle East and Africa (MEA)
- 10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033
- 11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033
- 12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033
- 13. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033
- 14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033
- 15. Market Structure Analysis
- 16. Competition Analysis
- 16.1. Johnson & Johnson (Janssen Global Services, LLC)
- 16.2. Boehringer Ingelheim GmbH
- 16.3. NeuroMetrix, Inc
- 16.4. Eli Lilly and Company
- 16.5. GlaxoSmithKline plc
- 16.6. Lupin Limited
- 16.7. Pfizer Inc
- 16.8. Astellas Pharma Inc
- 16.9. Glenmark Pharmaceuticals Ltd
- 16.10. Arbor Pharmaceuticals, LLC
- 16.11. Depomed, Inc
- 16.12. Other Prominent Players
- 17. Assumptions and Acronyms Used
- 18. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Value (US$ Mn) Analysis, by Disorder, 2018 to 2022
Table 02: Global Market Value (US$ Mn) Analysis, by Disorder, 2023 to 2033
Table 03: Global Market Value (US$ Mn) Opportunity Analysis, by Disorder, 2018 to 2022
Table 04: Global Market Value (US$ Mn) Opportunity Analysis, by Disorder, 2023 to 2033
Table 05: Global Market Value (US$ Mn) Analysis, by Treatment, 2018 to 2022
Table 06: Global Market Value (US$ Mn) Analysis, by Treatment, 2023 to 2033
Table 07: Global Market Value (US$ Mn) Opportunity Analysis, by Treatment, 2018 to 2022
Table 08: Global Market Value (US$ Mn) Opportunity Analysis, by Treatment, 2023 to 2033
Table 09: Global Market Value (US$ Mn) Analysis, by Distribution Channel, 2018 to 2022
Table 10: Global Market Value (US$ Mn) Analysis, by Distribution Channel, 2023 to 2033
Table 11: Global Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2018 to 2022
Table 12: Global Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2023 to 2033
Table 13: Global Market Value (US$ Mn) Analysis, by Region, 2018 to 2022
Table 14: Global Market Value (US$ Mn) Analysis, by Region, 2023 to 2033
Table 15: Global Market Value (US$ Mn) Opportunity Analysis, by Region, 2018 to 2022
Table 16: Global Market Value (US$ Mn) Opportunity Analysis, by Region, 2023 to 2033
Table 17: North America Market Value (US$ Mn) Analysis, by Region, 2018 to 2022
Table 18: North America Market Value (US$ Mn) Analysis, by Region, 2023 to 2033
Table 19: North America Market Value (US$ Mn) Opportunity Analysis, by Region, 2018 to 2022
Table 20: North America Market Value (US$ Mn) Opportunity Analysis, by Region, 2023 to 2033
Table 21: North America Market Value (US$ Mn) Analysis, by Disorder, 2018 to 2022
Table 22: North America Market Value (US$ Mn) Analysis, by Disorder, 2023 to 2033
Table 23: North America Market Value (US$ Mn) Opportunity Analysis, by Disorder, 2018 to 2022
Table 24: North America Market Value (US$ Mn) Opportunity Analysis, by Disorder, 2023 to 2033
Table 25: North America Market Value (US$ Mn) Analysis, by Treatment, 2018 to 2022
Table 26: North America Market Value (US$ Mn) Analysis, by Treatment, 2023 to 2033
Table 27: North America Market Value (US$ Mn) Opportunity Analysis, by Treatment, 2018 to 2022
Table 28: North America Market Value (US$ Mn) Opportunity Analysis, by Treatment, 2023 to 2033
Table 29: North America Market Value (US$ Mn) Analysis, by Distribution Channel, 2018 to 2022
Table 30: North America Market Value (US$ Mn) Analysis, by Distribution Channel, 2023 to 2033
Table 31: North America Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2018 to 2022
Table 32: North America Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2023 to 2033
Table 33: Latin America Market Value (US$ Mn) Analysis, by Region, 2018 to 2022
Table 34: Latin America Market Value (US$ Mn) Analysis, by Region, 2023 to 2033
Table 35: Latin America Market Value (US$ Mn) Opportunity Analysis, by Region, 2018 to 2022
Table 36: Latin America Market Value (US$ Mn) Opportunity Analysis, by Region, 2023 to 2033
Table 37: Latin America Market Value (US$ Mn) Analysis, by Disorder, 2018 to 2022
Table 38: Latin America Market Value (US$ Mn) Analysis, by Disorder, 2023 to 2033
Table 39: Latin America Market Value (US$ Mn) Opportunity Analysis, by Disorder, 2018 to 2022
Table 40: Latin America Market Value (US$ Mn) Opportunity Analysis, by Disorder, 2023 to 2033
Table 41: Latin America Market Value (US$ Mn) Analysis, by Treatment, 2018 to 2022
Table 42: Latin America Market Value (US$ Mn) Analysis, by Treatment, 2023 to 2033
Table 43: Latin America Market Value (US$ Mn) Opportunity Analysis, by Treatment, 2018 to 2022
Table 44: Latin America Market Value (US$ Mn) Opportunity Analysis, by Treatment, 2023 to 2033
Table 45: Latin America Market Value (US$ Mn) Analysis, by Distribution Channel, 2018 to 2022
Table 46: Latin America Market Value (US$ Mn) Analysis, by Distribution Channel, 2023 to 2033
Table 47: Latin America Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2018 to 2022
Table 48: Latin America Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2023 to 2033
Table 49: Europe Market Value (US$ Mn) Analysis, by Region, 2018 to 2022
Table 50: Europe Market Value (US$ Mn) Analysis, by Region, 2023 to 2033
Table 51: Europe Market Value (US$ Mn) Opportunity Analysis, by Region, 2018 to 2022
Table 52: Europe Market Value (US$ Mn) Opportunity Analysis, by Region, 2023 to 2033
Table 53: Europe Market Value (US$ Mn) Analysis, by Disorder, 2018 to 2022
Table 54: Europe Market Value (US$ Mn) Analysis, by Disorder, 2023 to 2033
Table 55: Europe Market Value (US$ Mn) Opportunity Analysis, by Disorder, 2018 to 2022
Table 56: Europe Market Value (US$ Mn) Opportunity Analysis, by Disorder, 2023 to 2033
Table 57: Europe Market Value (US$ Mn) Analysis, by Treatment, 2018 to 2022
Table 58: Europe Market Value (US$ Mn) Analysis, by Treatment, 2023 to 2033
Table 59: Europe Market Value (US$ Mn) Opportunity Analysis, by Treatment, 2018 to 2022
Table 60: Europe Market Value (US$ Mn) Opportunity Analysis, by Treatment, 2023 to 2033
Table 61: Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2018 to 2022
Table 62: Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2023 to 2033
Table 63: Europe Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2018 to 2022
Table 64: Europe Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2023 to 2033
Table 65: Asia Pacific Market Value (US$ Mn) Analysis, by Region, 2018 to 2022
Table 66: Asia Pacific Market Value (US$ Mn) Analysis, by Region, 2023 to 2033
Table 67: Asia Pacific Market Value (US$ Mn) Opportunity Analysis, by Region, 2018 to 2022
Table 68: Asia Pacific Market Value (US$ Mn) Opportunity Analysis, by Region, 2023 to 2033
Table 69: Asia Pacific Market Value (US$ Mn) Analysis, by Disorder, 2018 to 2022
Table 70: Asia Pacific Market Value (US$ Mn) Analysis, by Disorder, 2023 to 2033
Table 71: Asia Pacific Market Value (US$ Mn) Opportunity Analysis, by Disorder, 2018 to 2022
Table 72: Asia Pacific Market Value (US$ Mn) Opportunity Analysis, by Disorder, 2023 to 2033
Table 73: Asia Pacific Market Value (US$ Mn) Analysis, by Treatment, 2018 to 2022
Table 74: Asia Pacific Market Value (US$ Mn) Analysis, by Treatment, 2023 to 2033
Table 75: Asia Pacific Market Value (US$ Mn) Opportunity Analysis, by Treatment, 2018 to 2022
Table 76: Asia Pacific Market Value (US$ Mn) Opportunity Analysis, by Treatment, 2023 to 2033
Table 77: Asia Pacific Market Value (US$ Mn) Analysis, by Distribution Channel, 2018 to 2022
Table 78: Asia Pacific Market Value (US$ Mn) Analysis, by Distribution Channel, 2023 to 2033
Table 79: Asia Pacific Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2018 to 2022
Table 80: Asia Pacific Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2023 to 2033
Table 81: MEA Market Value (US$ Mn) Analysis, by Region, 2018 to 2022
Table 82: MEA Market Value (US$ Mn) Analysis, by Region, 2023 to 2033
Table 83: MEA Market Value (US$ Mn) Opportunity Analysis, by Region, 2018 to 2022
Table 84: MEA Market Value (US$ Mn) Opportunity Analysis, by Region, 2023 to 2033
Table 85: MEA Market Value (US$ Mn) Analysis, by Disorder, 2018 to 2022
Table 86: MEA Market Value (US$ Mn) Analysis, by Disorder, 2023 to 2033
Table 87: MEA Market Value (US$ Mn) Opportunity Analysis, by Disorder, 2018 to 2022
Table 88: MEA Market Value (US$ Mn) Opportunity Analysis, by Disorder, 2023 to 2033
Table 89: MEA Market Value (US$ Mn) Analysis, by Treatment, 2018 to 2022
Table 90: MEA Market Value (US$ Mn) Analysis, by Treatment, 2023 to 2033
Table 91: MEA Market Value (US$ Mn) Opportunity Analysis, by Treatment, 2018 to 2022
Table 92: MEA Market Value (US$ Mn) Opportunity Analysis, by Treatment, 2023 to 2033
Table 93: MEA Market Value (US$ Mn) Analysis, by Distribution Channel, 2018 to 2022
Table 94: MEA Market Value (US$ Mn) Analysis, by Distribution Channel, 2023 to 2033
Table 95: MEA Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2018 to 2022
Table 96: MEA Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2023 to 2033
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Value (US$ Mn) Historical Analysis, 2018 to 2022
Figure 02: Global Market Value (US$ Mn) Forecast and Analysis, 2023 to 2033
Figure 03: Global Market Value Y-o-Y Growth and Forecast, 2018 to 2033
Figure 04: Global Market Incremental $ Opportunity, 2023 to 2033
Figure 05: Global Market Share and BPS Analysis by Disorder, 2023 & 2033
Figure 06: Global Market Y-o-Y Growth Projections by Disorder, 2023 to 2033
Figure 07: Global Market Attractiveness Analysis by Disorder, 2023 to 2033
Figure 08: Global Market Value (US$ Mn) and Forecast by Peripheral Neuropathy, 2018 to 2033
Figure 09: Global Market Incremental $ Opportunity by Peripheral Neuropathy, 2023 to 2033
Figure 10: Global Market Value (US$ Mn) and Forecast by Autonomic Neuropathy, 2018 to 2033
Figure 11: Global Market Incremental $ Opportunity by Autonomic Neuropathy, 2023 to 2033
Figure 12: Global Market Value (US$ Mn) and Forecast by Proximal Neuropathy, 2018 to 2033
Figure 13: Global Market Incremental $ Opportunity by Proximal Neuropathy, 2023 to 2033
Figure 14: Global Market Value (US$ Mn) and Forecast by Focal Neuropathy, 2018 to 2033
Figure 15: Global Market Incremental $ Opportunity by Focal Neuropathy, 2023 to 2033
Figure 16: Global Market Share and BPS Analysis by Treatment, 2023 & 2033
Figure 17: Global Market Y-o-Y Growth Projections by Treatment, 2023 to 2033
Figure 18: Global Market Attractiveness Analysis by Treatment, 2023 to 2033
Figure 19: Global Market Share and BPS Analysis by Drug, 2023 & 2033
Figure 20: Global Market Y-o-Y Growth Projections by Drug, 2023 to 2033
Figure 21: Global Market Value (US$ Mn) and Forecast by Drug, 2018 to 2033
Figure 22: Global Market Incremental $ Opportunity by Drug, 2023 to 2033
Figure 23: Global Market Share and BPS Analysis by Radiotherapy, 2023 & 2033
Figure 24: Global Market Y-o-Y Growth Projections by Radiotherapy, 2023 to 2033
Figure 25: Global Market Value (US$ Mn) and Forecast by Radiotherapy, 2018 to 2033
Figure 26: Global Market Incremental $ Opportunity by Radiotherapy, 2023 to 2033
Figure 27: Global Market Share and BPS Analysis by Physiotherapy, 2023 & 2033
Figure 28: Global Market Y-o-Y Growth Projections by Physiotherapy, 2023 to 2033
Figure 29: Global Market Share and BPS Analysis by Region, 2023 & 2033
Figure 30: Global Market Y-o-Y Growth Projections by Region, 2023 to 2033
Figure 31: Global Market Attractiveness Analysis by Region, 2023 to 2033
Figure 32: North America Market Share and BPS Analysis by Country, 2023 & 2033
Figure 33: North America Market Y-o-Y Growth Projections by Country, 2023 to 2033
Figure 34: North America Market Attractiveness Analysis by Country, 2023 to 2033
Figure 35: North America Market Value (US$ Mn) Historical Analysis, 2018 to 2022
Figure 36: North America Market Value (US$ Mn) Forecast and Analysis, 2023 to 2033
Figure 37: North America Market Value Y-o-Y Growth and Forecast, 2018 to 2033
Figure 38: North America Market Incremental $ Opportunity, 2023 to 2033
Figure 39: North America Market Share and BPS Analysis by Disorder, 2023 & 2033
Figure 40: North America Market Y-o-Y Growth Projections by Disorder, 2023 to 2033
Figure 41: North America Market Attractiveness Analysis by Disorder, 2023 to 2033
Figure 42: North America Market Share and BPS Analysis by Treatment, 2023 & 2033
Figure 43: North America Market Y-o-Y Growth Projections by Treatment, 2023 to 2033
Figure 44: North America Market Attractiveness Analysis by Treatment, 2023 to 2033
Figure 45: North America Market Value (US$ Mn) and Forecast by Drug, 2018 to 2033
Figure 46: North America Market Incremental $ Opportunity by Drug, 2023 to 2033
Figure 47: North America Market Value (US$ Mn) and Forecast by Radiotherapy, 2018 to 2033
Figure 48: North America Market Incremental $ Opportunity by Radiotherapy, 2023 to 2033
Figure 49: Latin America Market Share and BPS Analysis by Country, 2023 & 2033
Figure 50: Latin America Market Y-o-Y Growth Projections by Country, 2023 to 2033
Figure 51: Latin America Market Attractiveness Analysis by Country, 2023 to 2033
Figure 52: Latin America Market Value (US$ Mn) Historical Analysis, 2018 to 2022
Figure 53: Latin America Market Value (US$ Mn) Forecast and Analysis, 2023 to 2033
Figure 54: Latin America Market Value Y-o-Y Growth and Forecast, 2018 to 2033
Figure 55: Latin America Market Incremental $ Opportunity, 2023 to 2033
Figure 56: Latin America Market Share and BPS Analysis by Disorder, 2023 & 2033
Figure 57: Latin America Market Y-o-Y Growth Projections by Disorder, 2023 to 2033
Figure 58: Latin America Market Attractiveness Analysis by Disorder, 2023 to 2033
Figure 59: Latin America Market Share and BPS Analysis by Treatment, 2023 & 2033
Figure 60: Latin America Market Y-o-Y Growth Projections by Treatment, 2023 to 2033
Figure 61: Latin America Market Attractiveness Analysis by Treatment, 2023 to 2033
Figure 62: Latin America Market Value (US$ Mn) and Forecast by Drug, 2018 to 2033
Figure 63: Latin America Market Incremental $ Opportunity by Drug, 2023 to 2033
Figure 64: Latin America Market Value (US$ Mn) and Forecast by Radiotherapy, 2018 to 2033
Figure 65: Latin America Market Incremental $ Opportunity by Radiotherapy, 2023 to 2033
Figure 66: Europe Market Share and BPS Analysis by Country, 2023 & 2033
Figure 67: Europe Market Y-o-Y Growth Projections by Country, 2023 to 2033
Figure 68: Europe Market Attractiveness Analysis by Country, 2023 to 2033
Figure 69: Europe Market Value (US$ Mn) Historical Analysis, 2018 to 2022
Figure 70: Europe Market Value (US$ Mn) Forecast and Analysis, 2023 to 2033
Figure 71: Europe Market Value Y-o-Y Growth and Forecast, 2018 to 2033
Figure 72: Europe Market Incremental $ Opportunity, 2023 to 2033
Figure 73: Europe Market Share and BPS Analysis by Disorder, 2023 & 2033
Figure 74: Europe Market Y-o-Y Growth Projections by Disorder, 2023 to 2033
Figure 75: Europe Market Attractiveness Analysis by Disorder, 2023 to 2033
Figure 76: Europe Market Share and BPS Analysis by Treatment, 2023 & 2033
Figure 77: Europe Market Y-o-Y Growth Projections by Treatment, 2023 to 2033
Figure 78: Europe Market Attractiveness Analysis by Treatment, 2023 to 2033
Figure 79: Europe Market Value (US$ Mn) and Forecast by Drug, 2018 to 2033
Figure 80: Europe Market Incremental $ Opportunity by Drug, 2023 to 2033
Figure 81: Europe Market Value (US$ Mn) and Forecast by Radiotherapy, 2018 to 2033
Figure 82: Europe Market Incremental $ Opportunity by Radiotherapy, 2023 to 2033
Figure 83: Asia Pacific Market Share and BPS Analysis by Country, 2023 & 2033
Figure 84: Asia Pacific Market Y-o-Y Growth Projections by Country, 2023 to 2033
Figure 85: Asia Pacific Market Attractiveness Analysis by Country, 2023 to 2033
Figure 86: Asia Pacific Market Value (US$ Mn) Historical Analysis, 2018 to 2022
Figure 87: Asia Pacific Market Value (US$ Mn) Forecast and Analysis, 2023 to 2033
Figure 88: Asia Pacific Market Value Y-o-Y Growth and Forecast, 2018 to 2033
Figure 89: Asia Pacific Market Incremental $ Opportunity, 2023 to 2033
Figure 90: Asia Pacific Market Share and BPS Analysis by Disorder, 2023 & 2033
Figure 91: Asia Pacific Market Y-o-Y Growth Projections by Disorder, 2023 to 2033
Figure 92: Asia Pacific Market Attractiveness Analysis by Disorder, 2023 to 2033
Figure 93: Asia Pacific Market Share and BPS Analysis by Treatment, 2023 & 2033
Figure 94: Asia Pacific Market Y-o-Y Growth Projections by Treatment, 2023 to 2033
Figure 95: Asia Pacific Market Attractiveness Analysis by Treatment, 2023 to 2033
Figure 96: Asia Pacific Market Value (US$ Mn) and Forecast by Drug, 2018 to 2033
Figure 97: Asia Pacific Market Incremental $ Opportunity by Drug, 2023 to 2033
Figure 98: Asia Pacific Market Value (US$ Mn) and Forecast by Radiotherapy, 2018 to 2033
Figure 99: Asia Pacific Market Incremental $ Opportunity by Radiotherapy, 2023 to 2033
Figure 100: MEA Market Share and BPS Analysis by Country, 2023 & 2033
Figure 101: MEA Market Y-o-Y Growth Projections by Country, 2023 to 2033
Figure 102: MEA Market Attractiveness Analysis by Country, 2023 to 2033
Figure 103: MEA Market Value (US$ Mn) Historical Analysis, 2018 to 2022
Figure 104: MEA Market Value (US$ Mn) Forecast and Analysis, 2023 to 2033
Figure 105: MEA Market Value Y-o-Y Growth and Forecast, 2018 to 2033
Figure 106: MEA Market Incremental $ Opportunity, 2023 to 2033
Figure 107: MEA Market Share and BPS Analysis by Disorder, 2023 & 2033
Figure 108: MEA Market Y-o-Y Growth Projections by Disorder, 2023 to 2033
Figure 109: MEA Market Attractiveness Analysis by Disorder, 2023 to 2033
Figure 110: MEA Market Share and BPS Analysis by Treatment, 2023 & 2033
Figure 111: MEA Market Y-o-Y Growth Projections by Treatment, 2023 to 2033
Figure 112: MEA Market Attractiveness Analysis by Treatment, 2023 to 2033
Figure 113: MEA Market Value (US$ Mn) and Forecast by Drug, 2018 to 2033
Figure 114: MEA Market Incremental $ Opportunity by Drug, 2023 to 2033
Figure 115: MEA Market Value (US$ Mn) and Forecast by Radiotherapy, 2018 to 2033
Figure 116: MEA Market Incremental $ Opportunity by Radiotherapy, 2023 to 2033
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What is the current size of the diabetic neuropathy market?
The global diabetic neuropathy market is valued at US$ 4.2 billion in 2023.
How big will the market be by the end of the forecast period?
Demand for diabetic neuropathy treatment is set to amass a revenue of US$ 8 billion by 2033-end.
At what CAGR will the market for diabetic neuropathy progress?
From 2023 to 2033, diabetic neuropathy demand is set to rise at 6.6% CAGR.
What percentage of diabetics have neuropathy?
Nearly 50% of all diabetic patients suffer from neuropathy.
Which diabetic neuropathy disorder is the most common?
Peripheral diabetic neuropathy is the most common type at present.
Diabetic Neuropathy Market